132 related articles for article (PubMed ID: 9167113)
21. Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat.
Hotta N; Kawamori R; Atsumi Y; Baba M; Kishikawa H; Nakamura J; Oikawa S; Yamada N; Yasuda H; Shigeta Y;
Diabet Med; 2008 Jul; 25(7):818-25. PubMed ID: 18644069
[TBL] [Abstract][Full Text] [Related]
22. The influence of aldose reductase on the oxidative burst in diabetic neutrophils.
Tebbs SE; Lumbwe CM; Tesfaye S; Gonzalez AM; Wilson RM
Diabetes Res Clin Pract; 1992 Feb; 15(2):121-9. PubMed ID: 1314160
[TBL] [Abstract][Full Text] [Related]
23. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
24. I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy.
Utsunomiya K; Narabayashi I; Nakatani Y; Tamura K; Onishi S
Clin Nucl Med; 1999 Jun; 24(6):418-20. PubMed ID: 10361937
[TBL] [Abstract][Full Text] [Related]
25. Changes in erythrocyte sorbitol concentrations measured using an improved assay system in patients with diabetic complications and treated with aldose reductase inhibitor.
Hayashi R; Hayakawa N; Makino M; Nagata M; Kakizawa H; Uchimura K; Hamada M; Aono T; Fujita T; Shinohara R; Nagasaka A; Itoh M
Diabetes Care; 1998 Apr; 21(4):672-3. PubMed ID: 9571366
[No Abstract] [Full Text] [Related]
26. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics.
Misawa S; Kuwabara S; Kanai K; Tamura N; Nakata M; Sawai S; Yagui K; Hattori T
Neurology; 2006 May; 66(10):1545-9. PubMed ID: 16717216
[TBL] [Abstract][Full Text] [Related]
27. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes.
Ohmura C; Watada H; Azuma K; Shimizu T; Kanazawa A; Ikeda F; Yoshihara T; Fujitani Y; Hirose T; Tanaka Y; Kawamori R
Endocr J; 2009; 56(1):149-56. PubMed ID: 18997444
[TBL] [Abstract][Full Text] [Related]
28. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils.
Suzuki K; Kawamura T; Sakakibara F; Sasaki H; Sano T; Sakamoto N; Hotta N
Diabet Med; 1999 Jan; 16(1):67-73. PubMed ID: 10229296
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms for luminol-augmented chemiluminescence from neutrophils induced by leukotriene B4 and N-formyl-methionyl-leucyl-phenylalanine.
Gyllenhammar H
Photochem Photobiol; 1989 Feb; 49(2):217-23. PubMed ID: 2540500
[TBL] [Abstract][Full Text] [Related]
30. Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma.
Uehara M; Sato N
Hepatology; 1994 Aug; 20(2):326-30. PubMed ID: 8045492
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
[TBL] [Abstract][Full Text] [Related]
32. Different effects of exogenous horseradish peroxidase on luminol-amplified chemiluminescence induced by soluble and particulate stimuli in human neutrophils.
Kopprasch S; Kohl M; Graessler J
J Biolumin Chemilumin; 1998; 13(5):267-71. PubMed ID: 9839190
[TBL] [Abstract][Full Text] [Related]
33. Epalrestat improves diabetic wound healing via increased expression of nerve growth factor.
Nakagaki O; Miyoshi H; Sawada T; Atsumi T; Kondo T; Atsumi T
Exp Clin Endocrinol Diabetes; 2013 Feb; 121(2):84-9. PubMed ID: 23426701
[TBL] [Abstract][Full Text] [Related]
34. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan.
Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y
J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467
[TBL] [Abstract][Full Text] [Related]
35. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
36. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus.
Steele JW; Faulds D; Goa KL
Drugs Aging; 1993; 3(6):532-55. PubMed ID: 8312678
[TBL] [Abstract][Full Text] [Related]
37. An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs.
Kasuya Y; Ito M; Nakamura J; Hamada Y; Nakayama M; Chaya S; Komori T; Naruse K; Nakashima E; Kato K; Koh N; Hotta N
Diabetologia; 1999 Dec; 42(12):1404-9. PubMed ID: 10651257
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
[TBL] [Abstract][Full Text] [Related]
39. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
40. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]